Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895773 | 1.00 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL19414808 | 1.00 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL28153746 | 0.95 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL927348 | 0.95 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL23477366 | 0.92 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL9544779 | 0.92 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL6219879 | 0.92 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL9727398 | 0.92 | HSD17B10 (0.59) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL28133679 | 0.91 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL28925069 | 0.91 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4107166-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180030075-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9796741-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9242985-B2 | Structural mimetics of proline-rich peptides and use thereof | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20140100217-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2014-04-10 | — | — | US | disclosed |
| WO-2013030111-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND USE THEREOF | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2013-03-07 | — | — | WO | disclosed |
| EP-2561873-A1 | Structural mimetics of proline-rich peptides and use of same | Forschungsverbund Berlin e.V. (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-0266568-A2 | Novel gamma-butyrolactone derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | HSD17B10 1124/4885SMN1; SMN2 2201/4885NPC1 1081/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 2328/4885SMN1; SMN2 2037/4885NPC1 245/4885 |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | HSD17B10 2518/4885SMN1; SMN2 4650/4885NPC1 1666/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 1063/4885SMN1; SMN2 3485/4885NPC1 488/4885 |
| US-20140100217-A1 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE | NPY1R, NPR1, NPY2R | HSD17B10 2437/4885SMN1; SMN2 114/4885NPC1 2006/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | HSD17B10 1063/4885SMN1; SMN2 3485/4885NPC1 488/4885 |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | HSD17B10 3773/4885SMN1; SMN2 1196/4885NPC1 3006/4885 |
| US-20180030075-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, F3 | HSD17B10 3597/4885SMN1; SMN2 1523/4885NPC1 2581/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | HSD17B10 3968/4885SMN1; SMN2 4623/4885NPC1 2733/4885 |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | HSD17B10 3877/4885SMN1; SMN2 890/4885NPC1 2278/4885 |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | CFD, CFH, TFPI | HSD17B10 1384/4885SMN1; SMN2 3115/4885NPC1 438/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | HSD17B10 1711/4885SMN1; SMN2 4032/4885NPC1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.